<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669474</url>
  </required_header>
  <id_info>
    <org_study_id>2008/219</org_study_id>
    <nct_id>NCT00669474</nct_id>
  </id_info>
  <brief_title>Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.</brief_title>
  <official_title>Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1: patients with essential hyperhidrosis are treated one time with suction curettage in&#xD;
      both axillae.&#xD;
&#xD;
      Part 2: patients with axillary hyperhidrosis receive one treatment with suction curettage in&#xD;
      one axilla, and at the same time one treatment with BOTOX injections in the other axilla.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study never started&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiviness and duration of effect of both treatments</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events of both treatments</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Essential Axillary Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Suction curettage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Botox</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Suction curettage</intervention_name>
    <description>Suction curettage</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with Botox</intervention_name>
    <description>Treatment with Botox</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 75 years&#xD;
&#xD;
          -  Persistent bilateral primary axillary hyperhidrosis&#xD;
&#xD;
          -  Hidrosis interferes with daily activities of patient&#xD;
&#xD;
          -  Gravimetrically minimal 50 mg spontaneous sweat production in each axilla, measured&#xD;
             during 5 minutes in room temperature in calm condition&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  patient can and shall continue the trial until the end, and will follow the&#xD;
             instructions correcly&#xD;
&#xD;
          -  women in reproductive period had a pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical condition that can be dangerous by treatment with BOTOX, including myastenia&#xD;
             gravis, Lambert-Eaton syndrome, ALS, and each other disease that can interfere with&#xD;
             the neuromuscular function&#xD;
&#xD;
          -  Secundary hyperhidrosis (for example secundary on hyperthyroid problems, lymfoma,&#xD;
             malaria)&#xD;
&#xD;
          -  Known allergy against study medication, his components, local anesthesia or iodium&#xD;
&#xD;
          -  Use of aminoglycosids, curare-like products, or other products which can interfere&#xD;
             with the neuromuscular function during the study&#xD;
&#xD;
          -  Use of therapy for hyperhidrosis with Aluminium chlorid during the study&#xD;
&#xD;
          -  Infection or skin disease in the area to treat&#xD;
&#xD;
          -  Participation in an other therapeutic study on the same time&#xD;
&#xD;
          -  Botuline toxine treatment in the last 4 months&#xD;
&#xD;
          -  Women who can or who want to become pregnant&#xD;
&#xD;
          -  Women in reproductive period who don't use the appropriate contraception&#xD;
&#xD;
          -  Patients in a situation of which the researchers decide it can be dangerous, or can&#xD;
             interfere with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katia Ongenae, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

